Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $152.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price raised by Stifel Nicolaus from $132.00 to $152.00 in a research report sent to investors on Tuesday morning, MarketBeat reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on KYMR. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They set a “hold” rating and a $120.00 price target for the company. TD Cowen raised shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Truist Financial raised their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Oppenheimer restated an “outperform” rating and set a $125.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.21.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $115.81 on Tuesday. The firm has a market capitalization of $9.63 billion, a PE ratio of -35.74 and a beta of 1.96. The stock’s fifty day moving average is $114.77 and its 200 day moving average is $97.82. Kymera Therapeutics has a fifty-two week low of $51.47 and a fifty-two week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. Kymera Therapeutics’s quarterly revenue was up 465.2% compared to the same quarter last year. Equities analysts forecast that Kymera Therapeutics will post -3.83 EPS for the current year.

Insider Buying and Selling

In related news, CEO Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the completion of the sale, the chief executive officer owned 666,568 shares in the company, valued at $76,848,624.72. This trade represents a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bruce Booth sold 45,367 shares of Kymera Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $107.06, for a total transaction of $4,856,991.02. Following the sale, the director owned 466,077 shares of the company’s stock, valued at $49,898,203.62. The trade was a 8.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 293,519 shares of company stock worth $33,451,157 over the last ninety days. 15.98% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after purchasing an additional 463 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the 4th quarter valued at $198,000. Empowered Funds LLC purchased a new stake in shares of Kymera Therapeutics in the 1st quarter worth $203,000. Finally, Nykredit A S purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter worth $207,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity.

Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them.